CONTEXT AND OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) has been increasingly diagnosed worldwide and is now recognized as a source of public health concern. It comprises a wide spectrum of histological features that range from simple steatosis to severe forms of fibrosis, steatohepatitis and even cirrhosis. The impact of bariatric surgery on the course of NAFLD in individuals with obesity has been extensively studied. DESIGN AND SETTING: Narrative review; public university hospital. METHODS: A comprehensive review was conducted based on an online search on the electronic databases MEDLINE and LILACS using the MeSH terms "fatty liver" and "bariatric surgery".
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is defined as accumulation of excessive fat in the liver in the absence of excessive drinking of alcohol and/or any secondary cause. [1] [2] [3] Along with obesity epidemics, it has been increasingly diagnosed over the last few decades and is now recognized as a source of public health concern. Today, NAFLD is considered to be the commonest liver disease worldwide. It comprises a wide spectrum of histological features that range from mild steatosis to severe forms of fibrosis, steatohepatitis and even cirrhosis. 3, 4 Epidemiology Today, the most reliable values for the prevalence of NAFLD and nonalcoholic steatohepatitis (NASH) in the general population in the Western world are 20-30% and 2-3%, respectively. [5] [6] [7] In Asia, the prevalence of NAFLD has been found to range from 15% to 30% in the general population. 8 The reported prevalence of NAFLD may vary according to the population studied and the diagnostic method used. The results from population-based studies provide more accurate data than do autopsies, hospital series or studies on high-risk groups, since they avoid higher selection bias. Studies that have detected NAFLD by means of liver enzyme levels have observed prevalences of NAFLD in the general population of between 3% and 23%, i.e. generally lower than those reported from analyses that used imaging methods. [5] [6] [7] [8] [9] [10] [11] Studies based on ultrasound scans appear to be more reliable and have shown prevalences of NAFLD among healthy adults of 25-30% in the United States and Italy and 29% in Japan. [5] [6] [7] [8] NAFLD is associated with significantly higher overall mortality, compared with the general population, particularly due to cardiovascular and liver-related complications. The histological stage is nevertheless crucial for the longer-term prognosis.
Among patients with NASH, compared with patients with simple steatosis, the prevalence of cirrhosis development within the first 15 years of follow-up is significantly higher (10.8% versus 0.7%, respectively) and liver-related mortality is also significantly higher (7.3% versus 0.9%). The overall and liver-related mortality among patients with NASH is correspondingly higher than would be expected among individuals of the same age and gender with simple NAFLD. [8] [9] [10] [11] Among obese populations with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM), the prevalence of NAFLD is much higher, ranging from about 50% to 90%. NAFLD has become a challenging public health concern, given that the prevalences of obesity and overweight have increased to epidemic levels over the last few decades. It constitutes an additional risk factor for this group of patients, especially because of the possibility of evolution to severe forms of liver fibrosis (including end-stage liver disease and cirrhosis) and even liver cancer. [5] [6] [7] [8] 12 Among cases labelled as "cryptogenic cirrhosis", the prevalence of NAFLD appears to be very high. Nayak et al. 9 The risk factors for development of NAFLD have been established. Increasing age presents a direct correlation with the prevalence of NAFLD. This is possibly related to the increasing insulin resistance and incidence of metabolic syndrome that occurs with age. 12 NAFLD generally occurs at a higher rate among men than among premenopausal women. It also differs according to ethnicity, such that it affects 45% of Hispanic people, 33% of
Caucasians and 24% of African-Americans in the United States and has been recorded at higher levels among South Asians in the United Kingdom. [7] [8] [9] [10] [11] [12] Likewise, among children and adolescents, the prevalence of NAFLD again seems to differ between different ethnic groups, with the highest prevalence in Hispanic people. 5 Several studies have revealed high rates of NAFLD among obese populations who undergo bariatric surgery. [13] [14] [15] [16] [17] Reports on morbidly obese populations have shown that the prevalence of liver fibrosis ranges from 6% to 74.4% and steatohepatitis from 26% to 55%.
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Pathophysiology
The underlying mechanisms that are present in the development of NAFLD are not completely understood, although much progress has been made over recent years. The classical pathogenetic pathway that leads to NAFLD was described as the "twohit hypothesis". This theory stated that damage to the liver tissue begins through triglyceride accumulation (the first hit), which functions as a sensitizing factor for secondary damage caused by inflammatory mediators (mainly cytokines or adipokines), mitochondrial dysfunction and oxidative stress (the second hits).
These secondary aggressions would lead to steatohepatitis and fibrosis. 18, 19 Today, it is widely recognized that free fatty acids (FFAs) also play a direct role in promoting liver injury. One of the consequences of insulin resistance (IR) is greater influx of FFAs to the liver: these undergo β-oxidation or esterification with glycerol to form triglycerides. Additionally, FFAs are able to cause toxicity through directly increasing oxidative stress and activating inflammatory pathways. 20, 21 Another "hit" that was recently identified consists of impaired hepatocyte proliferation. In NAFLD, when cell death occurs in the liver tissue, oxidative stress causes disruption to the regenerative process, thus leading to proliferation of hepatic progenitor (oval) cells. The size of the oval cell population correlates directly with the degree of fibrosis and it is believed that activation of these cells is involved in hepatic carcinogenesis. 18, [21] [22] [23] In NAFLD, lipid accumulation within the liver (steatosis) may result from several mechanisms: increased fat synthesis, increased fat delivery, decreased fat export and/or decreased fat oxidation. [23] [24] [25] [26] [27] [28] IR plays an important role in NAFLD development and evolution, and NAFLD also contributes towards worsening of IR.
In individuals with IR who present excess visceral fat, the influx of FFAs to the liver is increased, thus leading to both triglyceride accumulation and direct lipotoxicity. On the other hand, several abnormalities intrinsic to NAFLD impair insulin receptor signaling, especially FFAs, tumor necrosis factor-alpha (TNF-α), nuclear factor kappa B (NF-κB), ceramide, Jun N-terminal kinase 1 (JNK1), suppressors of cytokine signaling (SOCS) and cytochrome CYP2E1.
The cumulative effect generates a vicious cycle of IR and NAFLD worsening each other. 18, 23, [29] [30] [31] Steatosis is strongly associated with chronic hepatic inflammation, an effect that is partly mediated by activation of the Iκκ-β/NF-κB signaling pathway. This is associated with elevated hepatic expression of inflammatory cytokines such as TNF-α, interleukin-6 (IL-6) and interleukin 1-beta (IL-1β), and activation of Kupffer cells.
Both serum and hepatic levels of TNF-α are elevated in patients with NASH, and these levels are correlated with histological severity. 18, [32] [33] [34] [35] In addition to the proinflammatory effect, TNF-α promotes IR. Further data suggests that inflammation and NF-κB activation may also promote carcinogenesis and that this chronic inflammatory state may also play a key role in hepatocellular carcinoma (HCC) development. 18, 36, 37 Increased leptin levels are observed in cases of obesity and NAFLD. These are usually regarded as states of leptin resistance. It is possible that leptin may have an important role in the pathogenesis of NAFLD. Conversely, the circulating levels of adiponectin are inversely proportional to body fat content and become reduced in patients with NAFLD. [38] [39] [40] [41] Oxidative stress and mitochondrial dysfunction play a wellreported role in NASH, with a direct correlation between the degrees of oxidative stress and the severity of liver disease. Structural mitochondrial abnormalities and impairment of mitochondrial respiratory chain activity have been reported in human studies. 18, [42] [43] [44] [45] [46] Endoplasmic reticulum (ER) stress and endotoxemia derived from the gut microbiota are other mechanisms that appear to be implicated in NASH pathogenesis. ER stress is associated with various types of biological stress, such as hyperinsulinemia and hyperlipidemia, and it usually causes IR, inflammation, apoptosis and mitochondrial dysfunction, through several mechanisms. In cases of alcohol-related steatohepatitis, ER stress is a well-established pathophysiological factor, but further study on the possible role that it plays in the development of NASH is needed. 18 The role of gut bacterial overgrowth in the pathogenesis of NASH is now emerging through recent evidence. Bacterial overgrowth leads to production of ethanol and release of bacterial lipopolysaccharides, both of which can activate TNF-α production in Kupffer cells, thereby inducing inflammation in liver tissue. Individuals with NASH more frequently present bacterial overgrowth in the small intestine and increased gut permeability than do controls. These findings also suggest that this is a possible explanation for the rapid onset of NASH and liver fibrosis following jejunoileal bypass surgery. Furthermore, there is evidence that hepatic inflammation can be reduced by means of changes to the gut microbiota induced by antibiotics and probiotics. [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] Under high levels of oxidative stress, which is a feature usu- 
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Development of noninvasive scores for assessing liver disease, including NAFLD, is an important field of study nowadays. The ultimate goal in using these scores is to obtain reliable information from noninvasive laboratory and clinical variables that are available in general practice. The NAFLD fibrosis score is the one most used today and can easily be calculated based on six readily available variables: age, body mass index (BMI), hyperglycemia, platelet count, albumin and aspartate transaminase/alanine transaminase (AST/ALT) ratio. A meta-analysis on 13 studies that enrolled 3,064 patients showed that the NAFLD fibrosis score yielded an area under the receiver operating characteristic curve (AUROC) of 0.85 for predicting advanced fibrosis (bridging fibrosis or cirrhosis).
Scores ≤ -1.455 had 90% sensitivity and 60% specificity for ruling out advanced fibrosis, whereas scores > 0.676 had 67% sensitivity and 97% specificity for identifying the presence of advanced fibrosis. 85 However, this score does not replace liver biopsy and cannot in any manner be regarded as a gold standard, given that it does not provide a nuanced evaluation. On the other hand, it does not produce any morbidity and can be easily and readily assessed through routine studies. Thus, this score is quite adequate for populationbased studies and for clinical screening and follow-up purposes. 17, 84, 85 Despite recent developments in noninvasive methods for assessing NAFLD, liver biopsy remains the gold-standard method for diagnosing and characterizing it, since it may provide a nuanced evaluation that no other method is capable of today. On the other hand, it is expensive and highly invasive, and carries significant risk of morbidity and even mortality. 77 Moreover, the histological features of NAFLD and NASH are unevenly distributed throughout the entire liver parenchyma, and sampling error might result in substantial misdiagnosis and staging inaccuracies. 61, 78 The current guidelines state that use of biopsies should be restricted to individuals who would benefit the most from diagnostic and therapeutic guidance, and from prognostic perspectives. Hence, a biopsy should be considered for NAFLD assessment among patients:
1. with NAFLD, who are at increased risk of development of fibrosis and steatohepatitis;
2. with suspected NAFLD, in whom concurrent etiologies for hepatic steatosis and/or coexisting chronic liver diseases cannot otherwise be ruled out.
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Current clinical treatment
The current treatment strategies for NAFLD are based on the various aspects of its pathophysiology, especially its relationship with obesity and insulin resistance. The current nonsurgical strategies can be divided in non-pharmacological and pharmacological.
The primary goals of the main nonpharmacological strategies are weight loss and lifestyle changes. Interventions based on low-fat and low-calorie diets have been evaluated in several studies in which it was observed that these diets were associated with reductions in liver enzyme levels and liver fat content and improvement in liver histology. [87] [88] [89] [90] [91] [92] [93] Thoma et al. reviewed the efficacy of physical exercise alone versus physical exercise combined with dietary approaches to reduce liver fat content. Energy restriction and weight reduction of 4-14% resulted in significant decreases in hepatic steatosis of 35-81%. Decreases in liver fat correlated most strongly with the degree of weight loss. It was seen that regular exercise might modestly reduce steatosis even without a change in weight. 94 However, the greatest caveat of interventions that use dietary measures for weight loss is their lack of long-term durability. It remains unclear how weight regain affects the natural history of NAFLD/NASH.
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The primary goal of pharmacological interventions aimed towards NAFLD may either be weight loss or consist of a direct effect on liver disease and its pathophysiological features, especially insulin resistance and inflammation. Evidence regarding the effect of weight loss medications on NAFLD is scarce. The results relating to orlistat were inconclusive in several trials. 87, 98 Pentoxifylline, albeit not targeted for weight loss, led to a slight weight reduction and improvement in NASH in one trial. 99 Regarding insulin resistance, the potential therapeutic effect of insulin sensitizers on NAFLD/NASH has gathered much attention.
Rosiglitazone was shown to improve steatosis and aminotransferase levels in patients with NASH in a randomized controlled trial, 100 but its use is prohibited in Europe and very restricted in the United States because it may increase the risk of ischemic heart disease. 101 In randomized controlled trials, pioglitazone induced significant improvements in serum aminotransferase levels and liver histology (steatosis, inflammation, ballooning and Mallory-Denk bodies) in individuals with NASH. [102] [103] [104] However, the improvement in the extent of fibrosis was not significant. Use of pioglitazone is also prohibited in Europe, due to the risk of bladder cancer. 101 Use of metformin was not shown to provide any benefits or to have any independent therapeutic role in individuals with NAFLD, in a meta-analysis study. However, there is level III evidence that metformin may have a chemopreventive role in patients with diabetes and chronic liver disease, with reductions in the incidence of HCC and cholangiocarcinoma. 105 Liraglutide, an analogue of glucagon-like peptide 1 (GLP-1), was shown to promote significant improvement in liver histology in individuals with biopsy-proven NASH after 48 hours of therapy. Longer-term research is needed, but the initial results appear promising. 106 Use of vitamin E, because of its antioxidant effects, has shown benefits regarding liver histology among non-diabetic individuals with NASH. Nonetheless, it is important to emphasize that the safety of long-term usage of vitamin E is questionable, since high-dosage vitamin E supplements are associated with increased incidence of prostate cancer in healthy men, and with all-cause mortality.
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The current usage of lipid-lowering drugs targeted towards NAFLD (mainly statins) is so far unsupported by any substantial results from well-conducted studies. Thus, this practice is not recommended by American guidelines. 77, 101 The newer agent ezetimibe, which acts through inhibiting cholesterol absorption, has shown promising effects, especially in association with acarbose, but further results are needed in order to enable its use to be validated as a current recommendation. [111] [112] [113] [114] There is a lack of conclusive evidence supporting the use of ursodeoxycholic acid, N-3 polyunsaturated fatty acids, angiotensin receptor blockers, probiotics and synbiotics as validated treatment options for NAFLD.
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OBJECTIVE
The aim of this study was to conduct a critical analysis on the evidence available regarding the effect of bariatric surgery on NAFLD.
METHODS
A review of the literature was conducted through an online search for the MeSH terms "fatty liver" and "bariatric surgery" in MEDLINE (via PubMed) and LILACS (via BVS) ( Table 1) .
We included original studies that reported on clinical trials on the effects of several types of bariatric surgery on NAFLD. All the papers were checked according to their titles and abstracts Articles presenting potentially relevant studies were read and analyzed to assess their inclusion criteria. We excluded articles that consisted of in vitro or animal studies, articles in which the participants' characteristics did not match those mentioned above, poster session abstracts, review articles and other types of publications (non-standard bariatric surgical techniques; studies without appropriate follow-up; studies without appropriate NAFLD assessment; or studies with critical methodological issues). Other papers were used for contextualization and discussion.
RESULTS
There was significant overlap between the databases. After careful analysis, we selected three systematic reviews, seven prospective cohort studies and twelve retrospective cohort studies. N = number of individuals; RYGB = Roux-en-Y gastric bypass; VBG = vertical banded gastroplasty; GB = gastric banding; SG = sleeve gastrectomy; BPD-S = biliopancreatic diversion -Scopinaro; BPD-DS = biliopancreatic diversion -duodenal switch; MRI = magnetic resonance imaging US = ultrasound scan. Levels of evidence according to the Oxford classification -1a: systematic reviews (with homogeneity) of randomized controlled trials; 1b: individual randomized controlled trials (with narrow confidence interval); 1c: all or no randomized controlled trials; 2a: systematic reviews (with homogeneity) of cohort studies; 2b: individual cohort study or low-quality randomized controlled trials (e.g. < 80% follow-up); 2c: "outcomes" research; ecological studies; 3a: systematic review (with homogeneity) of case-control studies; 3b: individual case-control study; 4: case series (and poor quality cohort and case-control studies); 5: expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles".
summarizes the main articles found and their respective characteristics and reported results. [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] A schematic representation of the search in the online databases and the identification, exclusion and selection of the articles is presented in Figure 1 .
Bariatric surgery and NAFLD
The impact of bariatric surgery on the course of NAFLD in obese individuals has been extensively reported. Surgery plays a significant role in the expected natural history of NAFLD and usually leads to rapid changes in its evolution. Different surgical methods act within this context through a variety of mechanisms, which over the long term may be directly associated with the weight loss achieved, but over the short to medium term appear to be more related to acute structural and endocrine changes that are attributable to the procedures. Table 1 summarizes the main studies on the influence of bariatric surgery on NAFLD. In a historical cohort that enrolled 90 individuals who underwent liver biopsies during RYGB and one year afterwards, Mottin et al. 135 observed that the prevalence of hepatic steatosis at the In a retrospective analysis on paired needle liver biopsies taken during and following RYGB in 39 patients, Liu et al. 117 observed that the initial prevalences of hepatic pathological conditions were: steatosis (89.7%), hepatocellular ballooning (58.9%) and centrilobular/perisinusoidal fibrosis (50%). These improved significantly after RYGB: steatosis (2.9%), ballooning (0%) and centrilobular fibrosis (25%); significant decreases in the lobular inflammation score and stage of fibrosis were also noted. Nonetheless, no improvements were seen in portal tract inflammation or fibrosis.
Roux-en-Y gastric bypass
A controlled study conducted by Furuya et al., 118 which enrolled 18 individuals who underwent a wedge biopsy during RYGB and a percutaneous biopsy two years later, showed that, after a mean excess weight loss of 60%, steatosis disappeared in 84% of the patients, fibrosis in 75% and ballooning in 50%. A slight lobular inflammatory infiltrate remained in 81%, apparently unrelated to fatty degeneration.
Kakizaki et al. 140 conducted a prospective study that enrolled 84 participants, to compare the effects of RYGB on NAFLD in Japanese and non-Japanese individuals. They observed that when the body mass index (BMI) was similar, liver dysfunction among Japanese patients with severe obesity tended to be higher than among non-Japanese patients. Japanese patients with severe obesity would therefore need to reduce their body weight to a greater degree than would non-Japanese patients with the same BMI. The laboratory data and BMI were seen to be significantly improved, one year after laparoscopic RYGB, in both groups. In a large prospective study that enrolled 1236 participants, Caiazzo et al. 142 compared liver biopsy outcomes following RYGB and gastric banding. All NAFLD parameters improved after surgery. They all improved significantly more after RYGB than after gastric banding (percentage steatosis: one year, 7.9 versus 17.9; five years, 8.7 versus 14.5; NAS: one year, 0.7 versus 1.1; five years, 0.7 versus 1.0). In multivariate analysis, the superiority of RYGB was primarily but not completely explained by weight loss.
Abdennour et al. 121 conducted a prospective study that enrolled 243 individuals, with the main objective of studying the relationship between white adipose tissue evaluation methods and weight loss. These authors also observed significant improvement in liver enzymes one year after RYGB.
Cazzo et al. 122 conducted a prospective study in which they evaluated changes in NAFLD fibrosis score between the time of surgery and one year after RYGB. They observed that the mean score decreased from 1.142 to 0.066, and that surgery led to a resolution rate for advanced fibrosis of 55%. Resolution was statistically associated with female gender, the percentage of excess weight loss, post-surgical BMI, postsurgical platelet count and diabetes resolution.
In an exploratory study that compared 14 RYGB and 9 sleeve gastrectomy (SG) patients, Froylich et al. 143 observed that all morphological characteristics of NAS improved significantly after RYGB, whereas only steatosis and total NAS improved after SG. The state of fibrosis improved in both groups, but to a greater degree after RYGB. There were no significant differences in the decreases in NAS score after RYGB and SG procedures. These exploratory data support the idea that a randomized trial should be conducted to determine the differential effects of SG and RYGB on NAFLD.
Gastric banding and banded gastroplasty
Luyckx et al. 123 conducted a retrospective clinical analysis on 69 individuals who underwent liver biopsy during gastroplasty and a repeat biopsy later on, during the course of a mandatory surgical procedure. They observed that, after the drastic weight reduction, 45% of the histological observations were considered normal. Abnormal fattiness significantly decreased following surgery (38% versus 83% before). Furthermore, the severity of steatosis was significantly reduced in most cases: mild in 62% versus 21%, moderate in 23% versus 37% and severe in 15% versus 42%, after and before weight loss, respectively. However, a significant increase in hepatitis was observed, in 26% versus 14% before. Nevertheless, 87.5% of the cases were graded as mild and 12.5% as moderate, while no severe hepatitis was observed.
The prevalences of fibrosis and cirrhosis remained unchanged.
Busetto et al. 144 There were significant major improvements in lobular steatosis, necroinflammatory changes and fibrosis at the second biopsy.
Portal abnormalities remained unchanged. Eighteen patients had an initial fibrosis score of 2 or more, while only three patients showed this at the follow-up.
Jaskiewicz et al. 145 conducted a study on 10 individuals who underwent a wedge biopsy during gastroplasty and had a new repeat biopsy eight months later. They observed significant improvements of the degenerative and inflammatory hepatic lesions in the repeat biopsies and liver function readings, eight months after the surgery.
In a prospective study conducted by Phillips et al., 126 proton magnetic resonance spectroscopy and magnetic resonance imaging were used to estimate the quantities of lipids contained within the liver and abdominal subcutaneous and visceral compartments of 29 obese individuals, before gastric banding and three months afterwards. Significant reductions in body weight, abdominal fat and liver fat were observed three months after surgery. Changes in liver fat content were more closely associated with changes in serum gamma-glutamyl transferase than with changes in waist circumference.
Gastaldelli et al. 127 conducted a prospective study that evaluated 159 subjects with morbid obesity following laparoscopic adjustable gastric bypass. They observed that one year after gastric bypass, the patients' glucose tolerance, liver function tests and IR had improved; ferritin had not changed significantly but was still correlated with IR. The authors concluded that ferritin might be an additional useful marker for cases of hepatic IR of greater severity.
A prospective study by Moschen et al., 146 in which 30 individuals who underwent gastric bypass were enrolled, showed that the surgery improved IR, abnormal liver function tests and liver histology. Pronounced weight loss after 6 and 12 months was accompanied by significant increases in serum adiponectin levels, whereas both leptin and visfatin levels decreased. Serum levels of resistin increased after 6 months but fell below baseline values after 12 months. These results suggest that weight loss after gastric bypass surgery improves the adipocytokine milieu towards a more anti-inflammatory direction, both systemically and in the liver.
In a retrospective study that enrolled 16 individuals, Swierczynski et al. 147 observed significant improvements in several laboratory parameters, including serum phenylalanine, ALT, lipid concentrations and IR. A strong positive correlation between serum phenylalanine and serum ALT concentrations might suggest that the deterioration of liver function observed in obese patients contributes towards decreased phenylalanine metabolism and consequently towards increased serum phenylalanine concentration.
A prospective study was conducted by Frige et al. 148 with the aim of comparing the effects of gastric bypass and biliointestinal bypass (BIB) on glucose and lipid metabolism in NAFLD. There were 24 individuals in the gastric bypass group and 12 in the BIB group, and a significantly greater decrease in liver enzymes (ALT) was observed in the gastric bypass patients than in the BIB group.
Sleeve gastrectomy
In an analysis on prospective data gathered from 236 individuals, Karcz et al. 128 observed significant improvements in AST, ALT, triglycerides and high-density lipoprotein (HDL) levels one and three years after SG. NASH patients showed significant losses of body weight and amelioration of NASH status.
A retrospective study was conducted by Algooneh et al. 129 on 84 patients diagnosed with NAFLD prior to undergoing SG.
The diagnosis of NAFLD was achieved based on ultrasonographic imaging. A total of 47 patients (56%) showed complete resolution of NAFLD postoperatively. Multivariate analysis showed that there was significant resolution of NAFLD among the patients who achieved > 50% excess weight loss, after controlling for age and sex.
A prospective study conducted by Coupaye et al., 149 primarily to compare the nutritional effects of SG with those of RYGB, with 30 individuals in each group, also observed that transaminase levels were significantly lower after RYGB than after SG. This suggested that alterations in liver metabolism might affect synthesis or catabolism of some circulating lipids and proteins after RYGB.
Billeter et al. 150 conducted a retrospective matched study on a prospective database, to compare the effects of RYGB and SG on 34 individuals with morbid obesity. Both procedures significantly lowered ALT and aspartate aminotransferase (AST) after 12 months, but SG improved both liver function tests significantly better than RYGB did. In contrast to RYGB, SG normalized elevated ALT levels completely. In a study comparing 30 individuals who underwent paired liver biopsies during surgery and six months afterwards, Praveen-Raj et al. 151 reported that the individuals who underwent SG presented non-significant greater improvement of liver histology than those who underwent RYGB.
Biliopancreatic diversions
Scopinaro operation
In a retrospective analysis on 99 consecutive individuals who underwent surgery, Papadia et al. 130 noticed that AST levels at two months were significantly higher and then were significantly lower at 12 months. Hepatocellular necrosis in this series peaked at two months and decreased thereafter. The weight loss at two months, preoperative body weight, glucose levels and hepatic histology seemed to be of help in identifying patients at increased risk of acute liver damage, thus prompting the need for enhanced surveillance.
Ferrer Márquez et al. 131 conducted a prospective study on 76 obese individuals who underwent biopsy during surgery and 12-24 months afterwards. They observed that there was a significant decrease in overall NAFLD, with decreased inflammation and fibrosis. No cases of liver failure were observed.
Duodenal switch
In an analysis on 104 individuals who underwent the duodenal switch procedure and required further reoperation, Kral et al. and it was concluded that obesity surgery improved steatosis, necroinflammatory activity and hepatic fibrosis in patients with morbid obesity and NASH.
Johansson et al. 153 conducted a prospective cohort study on 10 individuals who underwent duodenal switch and 21 cases of RYGB.
Patients with morbid obesity treated by means of RYGB or duodenal switch showed sustained reductions in liver enzyme levels.
In a retrospective cohort study evaluating the influence of duodenal switch surgery on liver enzyme levels over a four-year period, among morbidly obese patients with normal aminotransferase and high baseline aminotransferase levels, Aller et al. 154 reported that significant decreases in ALT and AST activity levels occurred. The baseline percentages of high aminotransferase levels and the percentage of ALT/AST ratios that were < 1 were also found to be significantly lower at the one, two, three and four-year follow-ups in both groups.
Systematic reviews and synthesis
A meta-analysis conducted by Mummadi et al., 157 in which the surgical techniques analyzed were mixed, revealed that steatosis, steatohepatitis and fibrosis appeared to improve or become completely resolved in the majority of patients after bariatric surgeryinduced weight loss. These authors emphasized the limitations of their study, regarding mainly the vast heterogeneity of the overall designs and expected outcomes of the studies included.
Another meta-analysis, conducted by Bower et al., 156 revealed that bariatric surgery was associated with a significant reduction in the weighted incidence of a number of histological features of NAFLD, including steatosis (50.2%), fibrosis (11.9%), hepatocyte ballooning (67.7%) and lobular inflammation (50.7%); surgery was also associated with a reduction in liver enzyme levels. These authors emphasized that there was high heterogeneity among the methodologies and results, a factor that may have limited their analysis of these findings. A Cochrane review 157 that specifically addressed the lack of randomized clinical trials and high heterogeneity of the studies available acknowledged that the improvements regarding steatosis and inflammation seemed to be clear. However, it was concluded that the quality of the data available did not allow the authors to draw any unbiased conclusion relating to bariatric surgery for treating NASH. Despite the limitations of these studies, they represent the best level of evidence currently available on this topic.
There are some major concerns regarding research on the effects of bariatric surgery for treating NAFLD that need to be emphasized. Firstly, as is common among surgical studies, there is a lack of randomized controlled studies; in fact, the majority of studies are retrospective and non-controlled, and these aspects may produce data of poor quality. Secondly, and specifically regarding studies on NAFLD, there is no standardized measurement for the outcomes evaluated: some studies have evaluated liver biopsy specimens, while others have compared data from imaging studies or noninvasive methods for assessing liver disease. Thirdly, optimal evaluation of NAFLD is only possible by means of liver biopsies.
These can easily and safely be carried out at the time of the primary surgery, but this procedure is not widely available later on,
given that it is not risk-free and therefore performing it in individuals who do not require surgical interventions constitutes an ethical concern. This leads to great heterogeneity of outcomes that also cannot be ignored.
Despite the lack of controlled and randomized studies, there is a clear trend towards better results with regard to NAFLD outcomes among obese individuals who undergo surgery. It is also clear that the staging of NAFLD at the time of surgery is an important predictor of success, since it is noticeable that the rates of resolution for simple steatosis are much higher than those observed for steatohepatitis and especially for fibrosis.
Mechanisms underlying post-surgical improvements in NAFLD
The exact mechanisms that lead to improvement in NAFLD following bariatric surgery are probably strongly related to the metabolic changes that are involved in amelioration of metabolic syndrome (MetS). These changes occur early after the procedures, during a phase when no significant weight loss has yet been achieved. It is clear that while weight loss plays an important role in controlling metabolic abnormalities, this effect appears to be more significant over the long term. [158] [159] [160] Furthermore, there is evidence that excess weight is not the main pathophysiological feature relating to NAFLD. 158 The causes of early improvement of MetS after bariatric surgery are complex and relate to changes on the entero-insular axis mediated by gastrointestinal hormones called incretins. [160] [161] [162] The anatomical changes caused by the surgical procedures, particularly duodenal exclusion and overflow of nutrients to the distal small bowel, lead to release of incretins, especially glucagon-like peptide 1 (GLP-1) and gastrointestinal insulinotropic polypeptide (GIP). These increase the production and release of insulin, improve peripheral insulin sensitivity and favor an anorexic state.
Moreover, it appears that surgery enhances adipokine metabolism, which probably relates to increasing insulin sensitivity and promotes an anti-inflammatory effect by means of immunomodulation. 160 Recent research has indicated that surgery leads to changes in the gut microbiota and bile acid circulation that may be beneficial regarding MetS and NAFLD. [158] [159] [160] [161] [162] Furthermore, there is a decrease in portal influx of free fatty acids following surgery, which may be related both to feeding restrictions and to metabolic changes in visceral insulin sensitivity.
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International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) position statement
In the most recent IFSO consensus statement, 163 it is stated that bariatric surgery leads to reversal or significant improvement of NAFLD and NASH. Since the vast majority of the studies that led to this conclusion were non-randomized, non-controlled and observational cohort studies, this postulate constitutes a grade B recommendation, with evidence level 2. The IFSO also concluded that, despite the solid evidence available to date, further research, especially in randomized controlled settings, is necessary in order to reach ultimate conclusions. The high prevalence of NAFLD among the bariatric population also needs to be considered, as a significant factor. 17, 164, 165 Hence, taking into account the overall impact of bariatric surgery on obesity and obesityrelated comorbidities, such as NAFLD, this treatment option should be offered to the group of individuals who fulfill the current criteria of indications, as a potentially effective therapy.
Bariatric surgery in cirrhotic patients
Despite the increasing prevalence of obesity among the population with liver cirrhosis, along with the general epidemic of obesity, the number of studies on this topic is still limited. The main factors that need to be taken into account whenever a candidate for bariatric surgery is cirrhotic are the presence of portal hypertension and abnormalities of hepatocytic function. Regarding obese individuals who are also candidates for liver transplantation, the choice of technique and optimal timing for performing bariatric surgery are also significant issues that are not fully addressed in the current literature.
Among individuals with severe cirrhosis, surgical morbidity and mortality are significantly higher than what is observed in the general obese population. A retrospective study by Mosko et al. 166 that analyzed a national United States database found significantly higher mortality rates among cirrhotic individuals, both in those who were clinically compensated (0.9%) and in those who were not (16.3%), than among non-cirrhotic individuals (0.3%). Moreover, in low-volume centers, mortality reached 41% among non-compensated cirrhotic individuals. Dallal et al. 167 conducted a study that enrolled individuals with an incidental intraoperative diagnosis of liver cirrhosis, determined during bariatric surgery. They found that, among compensated cirrhotic individuals, RYGB presented a mortality rate similar to what was observed in the general population. However, it was also observed that episodes of transient renal failure, longer operation times and greater amounts of intraoperative bleeding and need for transfusion were more common within this group than in the general obese population. In a meta-analysis, Lazzati et al. 168 observed a mean excess weight loss of 66% among morbidly obese cirrhotic individuals over a two-year period, which was comparable to the general population.
SG was the surgical procedure most often performed, and the peri- sirolimus, mycophenolate sodium and cyclosporine. 169 Regarding access to the biliary tract, post-transplantation biliary strictures are common, occurring in up to 17% of the cases. 170 Taking these situations into consideration, SG appears to be the most appropriate technique for this group of individuals, since it does not affect drug absorption and enables endoscopic access to the biliary tract.
The optimal timing for performing bariatric surgery in individuals with cirrhosis who are also candidates for liver transplantation is yet to be determined. This surgery may be performed before, after or even during the transplantation. 171 One significant concern is the potential impact of obesity on the outcomes from liver transplantation. Recently, it was observed that surgical mortality, two-year survival and graft viability were similar in obese and lean individuals.
Perioperative morbidity was slightly higher. 172, 173 Because of the higher morbidity and mortality observed among non-compensated liver transplantation candidates, the pre-transplantation approach presents clear limitations. Bariatric procedures performed concomitantly with the transplantation have been reported; this approach has the potential to minimize the number of surgical procedures in high-risk individuals. However, it also requires concomitant availability of both surgical teams and generates the risk of combining the complications of both procedures. 174 Based on this latter finding, although there is no consensus yet, the approach that is best accepted is to perform the transplantation first and the bariatric surgery later on, among noncompensated cirrhotic individuals or among those with moderate to severe portal hypertension. According to the current literature, the morbidity is significantly higher, but the mortality is comparable.
175,176
Current situation and future perspectives NAFLD is becoming a public health concern worldwide today, and its prevalence is expected to grow even further in the near future. There is enough evidence to suggest that bariatric surgery should be considered to be the optimal treatment option for NAFLD by choice, and no longer only by chance. 177 It is expected that NAFLD may become the major reason for living-donor transplantation in the United States by 2030. 178 Although bariatric surgery is currently recognized as the standard treatment option for morbid obesity and its related comorbidities, the number of operations performed is far from sufficient to meet the need for intervention. In fact, less than 500,000 bariatric surgery procedures are performed worldwide every year today. This number represents less than 0.1% of the entire supposedly obese population. [179] [180] [181] Moreover, there are large numbers of subjects who do not fulfill the current indications for surgery but present harmful abnormalities relating to fat and glucose metabolism that can lead to and aggravate liver disease.
Hence, the most practical and effective action that can be implemented in relation to this entire disease chain is prevention. Encouragement towards practicing physical activity and following healthy low-fat/low-calorie diets needs to be extensively included in educational and community programs as early in life as possible, since obesity has become a pediatric issue too. 179, 180 Continuing education for healthcare professionals regarding liver disease and the methods for detecting, preventing and treating it should be mandatory. Screening of populations at high risk, in order to provide early diagnosis and staging of NAFLD, may also be carried out by means of simple laboratory tests and ultrasound scans. Early detection of MetS and diabetes and prompt management of these illnesses remain significant ways for preventing evolution to liver disease and its ominous severe forms. 180, 181 Regarding the role of bariatric surgery in relation to the clinical course of NAFLD, many questions remain to be answered.
Since there is a lack of randomized controlled trials, no ultimate conclusions can yet be provided. It is clear that the overall impact of bariatric surgery on NAFLD is positive, but the optimal surgical technique remains to be determined, as do the longer-term effects and the ways of maintaining the benefits achieved. Since there is also concern regarding the onset of persistent IR or even re-emergence of IR and T2DM 182, 183 among individuals who initially presented complete reversal, further research is needed in order to determine the influence of this event on liver histology. Another longer-term concern is the prevalence of weight regain, which may also have a significant effect on NAFLD.
Statement of human and animal rights
All procedures performed in the studies evaluated involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
CONCLUSION
The currently available evidence shows that bariatric surgery may become the treatment of choice for individuals with NAFLD.
It is important to emphasize that further research, especially by means of randomized controlled trials enrolling larger cohorts of individuals, is necessary in order to determine the optimal procedure for this group of subjects, as well as whether only individuals with morbid obesity might benefit from the effects of metabolic surgery, since there are vast numbers of lean and overweight individuals who also present NAFLD.
